Compare Johnson & Johnson (JNJ) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Prologis Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Prologis Inc trades at $129.49 (market cap $122.87B). The key difference: Johnson & Johnson is far larger — about 5× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Prologis Inc for 102 Days on average.
| JNJ | PLD | |
|---|---|---|
Market Cap | $618.09B | $122.87B |
Volume | 6,050,983 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $278.43 | $149.96 |
52-Week Low | $186.00 | $111.23 |
Typical Hold Time | 129 Days | 102 Days |
Enterprise Value | $646.37B | $157.61B |
Dividend Yield | 2.09% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Prologis (PLD) trades at $129.29, up 1.56% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported revenue of $8.79B in 2025 and has beaten EPS estimates for the last three quarters. Analyst consensus is bullish with a $155.15 price target, supported by robust leasing activity and data center growth, as highlighted in recent investor events (BofA Global Real Estate Conference, September 2026).
The outlook remains positive due to strong warehouse demand from e-commerce and data centers, though risks include rising debt levels and market volatility. With a P/E of 28.8 and net income margin of 45.79%, PLD offers growth potential, but investors should monitor debt-to-asset trends, which increased to 37.2% in 2025 from 34.05% in 2024.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
